Study Review | Thromboembolism, bleeding, & vascular death in nonvalvular atrial fibrillation patients with T2D receiving rivaroxaban or warfarin
Rivaroxaban Study Review Study Review | Thromboembolism, bleeding, & vascular death in nonvalvular atrial fibrillation patients with T2D receiving rivaroxaban or warfarin
Download this PDF

Learn more about Xarelto and order prescriber & patient resources here:

Order samples and resources
Bayer Australia Ltd. ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073. Xarelto® is a registered trademark of Bayer Group, Germany. Updated Dec 2021. PP-XAR-AU-1334-1
PBS Information: Authority Required (STREAMLINED). Refer to PBS Schedule for full authority information.
Please review the full product information (PI) before prescribing. Approved PI available here